BrightHeart
BrightHeart SAS is a Paris-based, privately held, pre-clinical medical device company and part of Sofinnova MD Start, Sofinnova Partners' medical device accelerator. The company’s software leverages the power of artificial intelligence to analyze fetal heart ultrasound exams and support clinicians with the prenatal identification of congenital heart defects. The technology aims to improve newborn outcomes by anticipating delivery care and early intervention. BrightHeart builds on an idea by Dr. Marilyne Levy and Dr. Bertand Stos, two leading fetal cardiologists based in Paris, France.
Sector
Medical Devices
Strategy
MD Start
Status
Live
Website
www.brightheart.fr
Related News
BrightHeart obtains third FDA clearance and PCCP approval, becoming first to offer one integrated solution for real-time fetal heart documentation and CHD detection
BrightHeart obtains second FDA clearance for expansion of platform capabilities - adding tablet support for fetal heart ultrasound evaluations
BrightHeart unveils breakthrough AI results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, revolutionizing prenatal care
BrightHeart secures FDA clearance for first AI software revolutionizing prenatal fetal heart ultrasound evaluations
BrightHeart appoints Michael Butchko as Chairman of the Board
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.